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Uma nova série de nove 3-fosfato-(4,4,4-trifluor-butil)-carbamatos de etila (compostos fosfato-
carbamato), foram obtidos através da reação de (4,4,4-trifluor-3-hidroxibut-1-il)-etil carbamatos 
com oxicloreto de fósforo seguido de adição de álcoois. Os produtos foram caracterizados por 
espectroscopia de RMN de 1H, 13C, 31P e 19F, CG-EM e análise elementar. Todos os compostos 
sintetizados foram testados para a inibição da enzima acetilcolinesterase (AChE) usando o 
método de Ellman. Todos os compostos analisados contendo os grupos carbamato e fosfato em 
sua estrutura, mostraram inibição enzimática, sendo que o composto contendo o grupo dietóxi 
(2b) apresentou a maior atividade inibitória. Estudos de modelagem molecular foram realizados 
para obter informações detalhadas entre o sítio ativo da enzima acetilcolinesterase e os compostos 
candidatos a inibição, obtendo-se valiosas informações estruturais com relação à inibição de 
enzima acetilcolinesterase.
A series of nine new [3-(disubstituted-phosphate)-4,4,4-trifluoro-butyl]-carbamic acid ethyl 
esters (phosphate-carbamate compounds) was obtained through the reaction of (4,4,4-trifluoro-3-
hydroxybut-1-yl)-carbamic acid ethyl esters with phosphorus oxychloride followed by the addition 
of alcohols. The products were characterized by 1H, 13C, 31P, and 19F NMR spectroscopy, GC-MS, 
and elemental analysis. All the synthesized compounds were screened for acetylcholinesterase 
(AChE) inhibitory activity using the Ellman method. All compounds containing phosphate and 
carbamate pharmacophores in their structures showed enzyme inhibition, being the compound 
bearing the diethoxy phosphate group (2b) the most active compound. Molecular modeling studies 
were performed to investigate the detailed interactions between AChE active site and small-molecule 
inhibitor candidates, providing valuable structural insights into AChE inhibition.
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Introduction
The synthesis of new phosphorus-containing 
compounds has been attracting a great deal of attention 
due to their impressive chemical and biological profiles.1 
Organophosphorus (OPs) compounds are important 
naturally occurring substrates in several biochemical 
processes, and tetracoordinate pentavalent phosphorus 
compounds are well known biologically active compounds.2 
The primary target for OPs is the acetylcholinesterase 
(AChE, EC 3.1.1.7), which is responsible for the 
regulation of cholinergic impulse.3 Furthermore, AChE 
is believed to play ‘non-classical’ roles in addition to its 
‘classical’ role in terminating synaptic transmission (e.g. 
as an adhesion protein). Both of these actions involve the 
so-called ‘peripheral’ anionic site at the entrance to the 
Zanatta et al. 1119Vol. 19, No. 6, 2008
active-site gorge.4 The AChE enzyme is an attractive target 
for therapeutic intervention not only because of its high 
catalytic efficiency, but also because of its important role 
in the central nervous system (CNS).5
The discovery of AChE inhibition, through the 
action of OPs compounds, allowed the development of 
insecticides and, to a limited extent, of new drugs.6 Both 
organophosphate and carbamate compounds have been 
extensively used as medicines and insecticides due to 
their inhibitory action of the AChE.7-10 Examples are 
Metrifonate,® used as antihelminthic and in the treatment 
of schistosamiasis, Echothiophate,® used for the treatment 
of glaucoma,11,12 and Rivastigmine® (a carbamate) used for 
the treatment of Alzheimer’s disease.13 
 Therefore, phosphate and carbamate frameworks 
are important pharmacophores required for potent 
anticholinesterase activity.14-16 Although, carbamates and 
OPs are potent inhibitors of AChE, the two chemical groups 
differ in the stability of their complexes with AChE.17
In spite of the important molecular recognition process 
involved in AChE inhibition for either phosphate or 
carbamate groups, the presence of both chemical moieties 
in the same molecule (inhibitor) is rarely found in the 
literature.18,19 In the present work, we have synthesized and 
fully characterized by means of 1H, 13C, 31P and 19F NMR 
spectroscopy, GC-MS, and elemental analysis, a new series 
of phosphate-carbamate compounds containing these two 
privileged pharmacophores in their structures, through the 
incorporation of phosphate groups in trifluoromethylated 
alcohols bearing a γ-ethyl carbamate function. In addition, 
the synthesized compounds were screened for AChE 
inhibitory activity and molecular modeling studies were 
subsequently carried out to investigate the preferred binding 
mode of these compounds in the AChE active site. It is 
worth noting that we described herein an efficient method 
for the synthesis of a new series of phosphate-carbamate 
compounds, using POCl3 as the phosphorilating reagent, 
instead of other traditional methods, with the advantage 
of reducing one reaction step.
Results and Discussion
Chemistry
Organophosphorus compounds such as phosphonate 
esters are generally prepared by the reaction of 
phosphonochloridates or phosphonodichloridates with 
alcohols. The use of phosphonochloridates is more 
common, and these compounds are prepared by the 
chlorination reaction of phosphonate diesters with 
phosphorus pentachloride (PCl5), or by treatment of 
phosphonate monoesters with thionyl chloride (SOCl2) or 
phosphonic acid (H3PO3) with oxalyl chloride (COCl)2.20,21 
Phosphorus oxychloride (POCl3) leads to the formation of 
some side products, and therefore, it has not been employed 
in the synthesis of organophosphorus compounds.22 In this 
study, we employed POCl3 sucessfully in the synthesis of 
the desired products. 
The 3-[(alkoxy-phosphoryloxy)-4,4,4-trifluoro-
butyl]-carbamic acid ethyl esters 2a-i were obtained 
through the reaction of (4,4,4-trifluoro-3-hydroxy-but-
1-yl)-carbamic acid ethyl esters 1a-c with phosphorus 
oxychloride, in toluene, in the presence of pyridine 
or triethylamine, under argon atmosphere, for 5 h, at 
room temperature. The ethyl 3-(chlorophosphonyloxy)-
4,4,4-trifluorobutylcarbamate intermediates were not 
isolated, and the addition of an excess of alcohols to these 
intermediates, furnished the compounds 2a-i as shown in 
Scheme 1. The synthesis of compounds 1a-c was described 
in a previous paper.23
When only an equivalent of the alcohols such as 
methanol, ethanol, iso-propyl, terc-butyl and benzyl were 
used, the reaction did not take place, and only the starting 
material was isolated. Other solvents, such as CH2Cl2 and 
CHCl3 were tested and did not furnish the desired products 
as well. When the reaction was carried out in THF the 
products were obtained but, in low yields. The products 
2a-i were purified by silica gel column chromatography 
and were analyzed by 1H, 13C, 19F and 31P NMR, GC-MS, 
and elemental analysis. These data are presented in the 
experimental section.
The formation of products 2a-i was evidenced by the 
following observations: i) typical multiplicity and coupling 
constants of the hydrogens located within 2 or 3 bonds from 
Scheme 1.
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the phosphorous atom (e.g. the alkoxy groups attached to 
the phosphorous atom); ii) the broad-band decoupled 13C 
NMR spectra showed doublets for the carbons within 2 or 
3 bonds from the phosphorous atom; iii) the 19F and 31P 
NMR spectra and the GC-MS spectra further confirm the 
structure of the obtained products. 
There was a concern about the correct structure of 
products 2 because the intermediate phosphonodichloridates 
could undergo intramolecular cyclization furnishing cyclic 
products such as oxazafosforinanes.24 However, no evidence 
of the formation of cyclic oxazafosforinanes was found 
through the analysis of the 1H, 13C, 19F, and 31P NMR, as well 
as GC-MS spectra or through elemental analysis. Figure 1 
shows the atom numbering used for the NMR assignment 
of compounds 2. 
Biochemical screening and molecular modeling studies
The synthesized compounds 2a-i were screened for 
AChE inhibitory activity at 1 µM, showing substantial 
inhibitory action (between 30 and 70%). These results 
confirm that the designed synthetic compounds containing 
the combined pharmacophores phosphate-carbamate are 
new modulators of AChE. Within this series, compound 2b 
showed the most promising inhibitory effects (inhibition 
of 70% at 1 µM), while compounds 2a and 2c, having a 
hydrogen in the R1 position (Scheme 1), showed inhibitions 
of 62 and 65%, respectively. For compounds 2d, 2e and 2f, 
bearing a methyl group at the R1 position, the effects were 
less pronounced as percentage of inhibition decreased to 49, 
52 and 50%, respectively. A more significant decrease in the 
inhibitory effects was observed for compounds 2g (34%), 
2h (38%) and 2i (30%), which have a phenyl group as the 
R1 substituent in their molecular structures. These results 
indicate that the presence of bulkier groups at the R1 has a 
negative impact on the modulation of AChE within this series 
of inhibitors combined pharmacophore characteristics. These 
interesting findings encourage us to extend our work with 
the aim of elucidating the possible binding mode of these 
compounds in the AChE active site. The understanding of the 
chemical basis involved in the complex process of molecular 
recognition and biological activity is of great importance in 
drug design.25 In this context, molecular modeling studies 
were carried out to investigate the preferred binding mode 
of this new series of synthetic AChE modulators possessing 
the two active pharmacophore moieties, which exhibit high 
capacity for intermolecular binding interactions in the protein 
active site.
The series of compounds 2a-i was analyzed in order to 
describe the possible interactions between the inhibitors and 
the amino acid residues of the active site, and from a region 
surrounding the cavity of the enzyme, called the peripheral 
site. Docking protocols as implemented in FlexX26,27 were 
employed to search the possible binding conformations of the 
ligands (2a-i, considering both S and R configurations) into 
the AChE binding site. The X-ray crystallographic data for 
o-ethylmethylphosphonylated AChE from Torpedo californica 
were retrieved from the Protein Data Bank (PDB code 1VXR). 
Considering the high homology between T. californica AChE 
and Electrophorus electricus AChE, the crystallographic and 
biological data employed in this work are appropriate for 
the structural studies. Additionally, docking procedures as 
implemented in GOLD 3.0 were performed and the bioactive 
conformations obtained were in good agreement with those 
obtained with FlexX. AChE inhibitors 2a and 2b were the two 
of more significant results in the molecular modeling studies. 
For instance, Figure 2a shows the complex of AChE with the 
inhibitor (S)-2b, while Figure 2b shows the AChE in complex 
with (R)-2b. Figure 2 depict intermolecular interactions in the 
active site found to be essential in stabilizing the transition state 
(for instance, the catalytic triad of residues Ser200, His440 
and Glu327) as well as other important amino acid residues 
of the peripheral site.
As can be seen in Figure 2, the docking results (for all 
compounds) indicate that the phosphate group interacts 
with residue Ser200 of catalytic triad, playing an important 
role on the molecular recognition process as well as on the 
inhibitory effects of this series of phosphate-carbamate 
compounds. Additionally, inhibitors (S)-2a and (S)-2b 
Figure 1. Atom numbering used for the NMR assignment of compounds 2.
Figure 2a. Molecular interactions between AChE and the inhibitor 
(S)-2b, (displayed in pink). Residues of active site (Ser200 and His440) are 
displayed in green and residue of the peripheral site (Phe330) is displayed 
in violet. Hydrogen bond is shown in dashed lines.
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seem to stabilize the active site through hydrogen bond 
interactions between their carbamate group and the 
residue Phe330 in the peripheral site. Distances of 1.85 Å 
and 2.12 Å were observed from the NH hydrogen of the 
carbamate group to the carbonyl oxygen of Phe330 for 2a 
and 2b, respectively (Figure 2a). Similar hydrogen bonds 
between the carbamate group and the carbonyl oxygen of 
Trp84 and hydroxyl hydrogen of Ser122 were found in 
inhibitors (R)-2a and (R)-2b (Figure 3).
Nearly 70% of the surface of the AChE cavity is covered 
by aromatic rings. Hydrophobic contacts between inhibitor 
(S)-2b and the aromatic side chains of the residues located 
in the peripheral site (Trp279, Phe290 and Phe331) are 
also important components in the stabilization of enzyme-
inhibitor complexes.
Conclusion
In this work, we have developed an efficient procedure 
for the preparation of phosphate-carbamate compounds 
from the reaction of (4,4,4-trifluoro-3-hydroxy-but-1-yl)-
carbamic acid ethyl esters with POCl3 followed by the 
addition of an appropriate alcohol. This synthetic approach 
employs inexpensive reagents, and the phosphonodichloridate 
intermediates underwent in situ conversion into the 
corresponding products by the addition of an excess of the 
alcohols, without the formation of cyclic oxazafosforinanes. 
The biochemical screening was important to reveal the AChE 
inhibitory effects for the new series of synthesized compounds. 
The molecular modeling studies allowed the identification of 
the possible binding mode of these compounds in the AChE 
active site. Together, the results provide valuable information 
on how this new molecular scaffold, represented by the 
compounds containing both active phosphate and carbamate 
pharmacophores, interacts with AChE. Nevertheless, it would 
be interesting to overcome some of the remaining challenges 
for the elucidation of the mechanism of action of this new 
class of AChE inhibitors with further biochemical evaluation 
and mechanism of action studies.
Experimental
Toluene was purified and dried before use and the 
γ-aminoalcohols (4,4,4-trifluoro-3-hydroxy-but-1-yl)-
carbamic acid ethyl esters were prepared according to the 
reference.23 Column chromatography was carried out in silica 
gel Aldrich 60A (230-400 mesh), using a mixture of adequate 
solvents. 1H NMR spectra were registered on a Bruker DPX 
200 spectrometer (1H at 200.13 MHz) in CDCl3, using TMS 
as the internal reference. 13C, 31P and 19F NMR spectra were 
registered on a Bruker DPX 400 at 100.62, 162.00, and 376.5 
MHz, respectively, in CDCl3. TMS was used as the internal 
reference for the 13C NMR spectra. Hydrogen broad-band 
decoupled 31P NMR spectra were registered in 10 mm tubes, 
in CDCl3, using H3PO4 as the external reference (insert tube). 
19F NMR spectra were registered in 5 mm tubes, in CDCl3 
using fluorobenzene as the external reference (insert tube). 
Mass spectra were registered on a HP 5973 MSD connected 
to a HP 6890 GC and interfaced by a Pentium PC. The GC 
was equipped with a split-splitless injector, autosampler, cross-
linked HP 5 capillary column (30 m of length, 0.32 mm of 
internal diameter, and 0.25 µm of film thickness), and helium 
was used as the carrier gas. The CHN elemental analysis was 
performed on an EA 1110 Carlo Erba Instrument (University 
of São Paulo, São Carlos, SP, Brazil). 
Acetylthiocholine iodide, acetylcholine acetylhydrolase 
(AChE from Electrophorus electricus) and DTNB 
(5,5’-dithiobis-2-nitrobenzoic acid) were purchased from 
Sigma Chemical Co. (St. Louis, MO, USA). 
Molecular modeling studies were performed using the 
SYBYL 7.3 package (Tripos Inc., St. Louis, USA) run 
on Red Hat Enterprise Linux workstations, as previously 
described.26,27 The 3D structures of the inhibitors were 
constructed using standard geometric parameters of 
molecular modeling software package SYBYL 7.3. Each 
single optimized conformation of each molecule in the data 
Figure 2b. Molecular interactions between AChE and the inhibitor 
(R)-2b, (displayed in pink). Residues of the active site (Ser200 and His440) 
are displayed in green and residues Trp84 and Ser122 are displayed in 
violet. Hydrogen bond is shown in dashed lines.
Figure 3. Hydrophobic contacts between the inhibitor (S)-2b (displayed 
in pink) and residues of the peripheral site (Trp279, Phe290 and Phe331, 
colored in violet).
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set was energetically minimized employing Tripos force 
field and Gasteiger-Hückel charges.
General procedure for the synthesis and purification of 
compounds 2a-i
A solution of 1 (1.0 mmol) in toluene (8.0 mL) was stirred 
and refluxed under argon atmosphere in a Dean-Stark for 
1h. The solution was allowed to cool at room temperature 
and pyridine (0.16 mL, 2 mmol) was added. The solution 
was stirred for 5 min and then cooled at 0 °C. POCl3 (0.1 
mL, 1 mmol) was added to the reaction and after 10 min the 
ice bath was removed. The stirring was continued for 5 h at 
room temperature when the presence of a solid was observed. 
Alcohols (1 mL) were added to the reaction vessel and stirring 
was continued for 0.5 h at room temperature. The solvent was 
removed by rotatory evaporator, CH2Cl2 (15 mL) was added 
and the solution was washed with water (3 × 10 mL). The 
aqueous layer was extracted with CH2Cl2 (2 × 10 mL). The 
organic layers were combined, dried (MgSO4), and the solvent 
was removed by rotatory evaporator. Yields, 1H, 13C, 31P and 
19F NMR, and GC-MS data and the elemental analysis of the 
compounds are presented in the experimental section. The 
compounds 2a-i were purified by column chromatography on 
silica gel Aldrich 60A (230-400 Mesh), using chloroform with 
1, 2 or 5% of methanol as eluant; 1% (for 2l and 2o), 2% (for 
2a-b, 2d-e, 2g-h, 2k, and 2m) and 5% (for 2c, 2f, 2i-j, 2n). 
[3-(Dimethoxy-phosphate)-4,4,4-trifluoro-butyl]-carbamic 
acid ethyl ester (2a)
Yellow oil, 70%; MS EI (70ev): m/z (%) = 278 (M+-45, 
7), 127 (100), 109 (18); 1H NMR (CDCl3/TMS, 200.13 
MHz) d 1.23 (t, 3H, JH8-H7 = 7.0 Hz, H-8), 1.84 – 1.91 (m, 
1H, H-3), 2.08 – 2.10 (m, 1H, H-3), 3.17 – 3.20 (m, 1H, H-4), 
3.55 – 3.63 (m, 1H, H-4), 3.81 (d, 3H, JH9-P = 11.6 Hz, H-9), 
3.83 (d, 3H, JH9-P = 11.2 Hz, H-9’), 4.11 (q, 2H, JH7-H8 = 7.0 
Hz, H-7), 4.71 – 4.76 (m, 1H, H-2), 5.66 (brs, 1H, NH); 13C 
NMR (CDCl3/TMS, 100 MHz) d 14.2 (C-8), 29.3 (C-3), 35.4 
(C-4), 54.6 (C-9), 60.5 (C-7), 72.4 (qd, JC-F = 32.7 Hz, JC-P = 
3.6 Hz, C-2), 123.3 (qd, JC-F = 278.7 Hz, JC-P = 6.4 Hz, CF3), 
156.6 (C-6); 19F NMR (CDCl3/fluorobenzene, 376.5 MHz) d 
-77.78; 31P NMR (CDCl3/H3PO4, 162.0 MHz) d 0.92; Anal. 
Calcd for C9H17F3NO6P (323.21): C, 33.45; H, 3.30; N, 4.33. 
Found: C, 33.45; H, 3.50; N, 4.33.
[3-(Diethoxy-phosphate)-4,4,4-trifluoro-butyl]-carbamic 
acid ethyl ester (2b)
Yellow oil, 50%; MS EI (70ev): m/z (%) = 306 (M+-
45, 10), 278 (5), 250 (17), 155 (100), 127 (57); 1H NMR 
(CDCl3/TMS, 200.13 MHz) d 1.23 (t, 3H, JH8-H7 = 7.2 Hz, 
H-8), 1.37 (dt, 3H, JH10-H9 = 7.0 Hz, JH10-P = 1.2 Hz, H-10), 
1.39 (dt, 3H, JH10’-H9’ = 7.0 Hz, JH10’-P = 1.2 Hz, H-10’), 1.84 
– 1.93 (m, 1H, H-3), 2.05 – 2.18 (m, 1H, H-3), 3.15 – 3.22 
(m, 1H, H-4), 3.60 – 3.66 (m, 1H, H-4), 4.09 – 4.25 (m, 
6H, H-7, H-9, H-9’), 4.63 – 4.82 (m, 1H, H-2), 5.80 (brs, 
1H, NH); 13C NMR (CDCl3/TMS, 100 MHz) d 15.6 (C-
8), 15.9 (JC-P = 7.1 Hz, C-10), 29.2 (C-3), 35.4 (C-4), 60.7 
(C-7), 63.5 (d, JC-P = 5.6 Hz, C-9), 64.7 (d, JC-P = 6.6 Hz, 
C-9’), 72.2 (qd, JC-F = 32.4 Hz, JC-P = 4.9 Hz, C-2), 123.5 
(qd, JC-F = 278.8 Hz, JC-P = 6.3 Hz, CF3), 156.6 (C-6); 19F 
NMR (CDCl3/fluorobenzene, 376.5 MHz) d -77.68; 31P 
NMR (CDCl3/H3PO4, 162.0 MHz) d -1.16; Anal. Calcd for 
C11H21F3NO6P (351.26): C, 37.61; H, 6.03; N, 3.99. Found: 
C, 37.81; H, 6.01; N, 3.74.
[3-(Bis-allyloxy-phosphate)-4,4,4-trifluoro-butyl]-carbam-
ic acid ethyl ester (2c) 
Yellow oil, 40%; MS EI (70ev): m/z (%) = 330 (M+-45, 
6), 318 (6), 179 (100), 124 (22), 110 (10); 1H NMR (CDCl3/
TMS, 200.13 MHz) d 1.20 (t, 3H, JH8-H7 = 6.6 Hz, H-8), 
1.74 – 1.88 (m, 1H, H-3), 1.97 – 2.10 (m, 1H, H-3), 3.16 
– 3.29 (m, 1H, H-4), 3.46 – 3.57 (m, 1H, H-4), 4.06 – 4.16 
(m, 2H, H-7), 4.47 – 4.63 (m, 4H, H-9), 4.66 – 4.76 (m, 
1H, H-2), 5.16 – 5.43 (m, 4H, H-11), 5.84 – 6.02 (m, 2H, 
H-10); 13C NMR (CDCl3/TMS, 100 MHz) d 14.4 (C-8), 
29.0 (C-3), 35.3 (C-4), 60.6 (C-7), 68.0 (d, JC-P = 5.8 Hz, 
C-9), 68.8 (d, JC-P = 5.4 Hz, C-9’), 72.3 (qd, JC-F = 32.7 Hz, 
JC-P = 4.3 Hz, C-2), 118.1 (C-11), 118.9 (C-11’), 131.6 (d, 
JC-P = 7.1 Hz, C-10), 132.2 (d, JC-P = 7.0 Hz, C-10’), 156.6 
(C-6); Anal. Calcd for C13H21F3N3O6P (375.28): C, 41.61; 
H, 5.64; N, 3.73. Found: C, 41.73; H, 5.95; N, 3.33.
[3-(Dimethoxy-phosphate)-4,4,4-trifluoro-1-methyl-butyl]-
carbamic acid ethyl ester (2d) 
Yellow oil, 98%; MS EI (70ev): m/z (%) = 292 (M+-45, 
7), 249 (2), 211 (5), 127 (100), 109 (21), 96 (15), 70 (26); 
1H NMR (CDCl3/TMS, 200.13 MHz) d 1.23 (t, 3H, JH8-H7 
= 7.4 Hz, H-8), 1.26 (d, 3H, JCH3-H4 = 6.2 Hz, CH3), 1.83-
1.92 (m, 1H, H-3), 2.04 – 2.11 (m, 1H, H-3), 3.77 (d, 3H, 
JH9-P = 11.0 Hz, H-9), 3.79 (d, 3H, JH9’-P = 10.8 Hz, H-9’), 
3.85 – 3.97 (m, 1H, H-4), 4.10 (q, 2H, JH7-H8 = 7.0 Hz, H-7), 
4.71 – 4.79 (m, 1H, H-2), 5.00 (brs, 1H, NH); 13C NMR 
(CDCl3/TMS, 100 MHz) d 14.3 (C-8), 19.9 (CH3), 36.2 
(C-3), 43.1 (C-4), 54.1 (d, JC-P = 5.5 Hz, C-9), 54.5 (d, JC-P 
= 6.3 Hz, C-9), 60.5 (C-7), 72.5 (qd, JC-F = 33.0 Hz, JC-P 
= 5.0 Hz, C-2), 123.3 (qd, JC-F = 279.3 Hz, JC-P = 5.9 Hz, 
CF3), 155.8 (C-6); 19F NMR (CDCl3/fluorobenzene, 376.5 
MHz) d -77.94; 31P NMR (CDCl3/H3PO4, 162.0 MHz) d 
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-0.22; Anal. Calcd for C10H19F3NO6P (337.23): C, 35.62; 
H, 5.68; N, 4.15. Found: C, 35.63; H, 5.71; N, 4.06.
[3-(Diethoxy-phosphate)-4,4,4-trifluoro-1-methyl-butyl]-
carbamic acid ethyl ester (2e) 
Yellow oil, 43%; MS EI (70ev): m/z (%) = 320 (M+-45, 
10), 292 (3), 250 (14), 155 (100), 127 (42), 70 (25); 1H 
NMR (CDCl3/TMS, 200.13 MHz) d 1.23 (t, 3H, JH8-H7 = 
6.8 Hz, H-8), 1.26 (d, 3H, JCH3-H4 = 6.4 Hz, CH3), 1.34 (dt, 
3H, JH10-H9 = 7.2 Hz, JH10-P = 0.8 Hz, H-10), 1.37 (dt, 3H, 
JH10’-H9’ = 7.2 Hz, JH10’-P = 0.8 Hz, H-10’), 1.86 – 1.90 (m, 
1H, H-3), 2.05 – 2.12 (m, 1H, H-3), 3.90 – 3.93 (m, 1H, 
H-4), 4.10 (q, 2H, JH7-H8 = 6.8 Hz, H-7), 4.07 – 4.22 (m, 
6H, H-7, H-9, H-9’), 4.70 – 4.75 (m, 1H, H-2), 5.01 (brs, 
1H, NH); 13C NMR (CDCl3/TMS, 100 MHz) d 14.4 (C-8), 
15.9 (d, JC-P = 7.8 Hz, C-10), 16.0 (d, JC-P = 6.1 Hz, C-10), 
20.4 (CH3), 36.3 (C-3), 43.4 (C-4), 60.6 (C-7), 63.5 (d, 
JC-P = 5.7 Hz, C-9), 64.5 (d, JC-P = 6.7 Hz, C-9’), 72.3 (qd, 
JC-F = 33.0 Hz, JC-P = 4.8 Hz, C-2), 123.5 (qd, JC-F = 278.8 
Hz, JC-P = 6.3 Hz, CF3), 155.8 (C-6); 19F NMR (CDCl3/
fluorobenzene, 376.5 MHz) d -77.86; 31P NMR (CDCl3/
H3PO4, 162.0 MHz) d -1.76; Anal. Calcd for C12H23F3NO6P 
(365.28): C, 39.46; H, 6.35; N, 3.83. Found: C, 39.46; H, 
6.35; N, 3.83. 
[3-(Bis-allyloxy-phosphate)-4,4,4-trifluoro-1-methyl-
butyl]-carbamic acid ethyl ester (2f) 
Yellow oil, 40%; MS EI (70ev): m/z (%) = 344 (M+-
45, 6), 179 (100), 211 (15), 139 (36), 124 (39); 1H NMR 
(CDCl3/TMS, 200.13 MHz) d 1.23 (t, 6H, JH8-H7 = 7.0 Hz, 
H-8, CH3), 1.83 – 1.94 (m, 1H, H-3), 2.02 – 2.17 (m, 1H, 
H-3), 3.89 – 3.92 (m, 1H, H-4), 4.10 (q, 2H, JH7-H8 = 7.0 Hz, 
H-7), 4.53 – 4.64 (m, 4H, H-9), 4.69 – 4.81 (m, 1H, H-2), 
5.23 – 5.44 (m, 4H, H-11), 5.86 – 6.03 (m, 2H, H-10); 13C 
NMR (CDCl3/TMS, 100 MHz) d 14.2 (C-8), 19.9 (CH3), 
36.0 (C-3), 43.0 (C-4), 60.2 (C-7), 67.9 (d, JC-P = 4.9 Hz, 
C-9), 68.5 (d, JC-P = 6.3 Hz, C-9’), 72.6 (qd, JC-F = 33.7 Hz, 
JC-P = 5.1 Hz, C-2), 117.1 (d, JC-P = 4.2 Hz, C-11), 118.4 (d, 
JC-P = 6.9 Hz, C-11), 123.2 (qd, JC-F = 278.2 Hz, JC-P = 6.0 
Hz, CF3), 131.6 (d, JC-P = 4.0 Hz, C-10), 132.0 (d, JC-P = 
6.9 Hz, C-10), 155.8 (C-6); Anal. Calcd for C14H23F3NO6P 
(389.31): C, 43.19; H, 5.95; N, 3.60. Found: C, 42.63; H, 
5.39; N, 3.49.
[3-(Dimethoxy-phosphate)-4,4,4-trifluoro-1-phenyl-butyl]-
carbamic acid ethyl ester (2g) 
Yellow oil, 40%; MS EI (70ev): m/z (%) = 399 (2), 
273 (16), 244 (100), 200 (68), 77 (29); 1H NMR (CDCl3/
TMS, 200.13 MHz) d 1.20 (t, 3H, JH8-H7 = 7.0 Hz, H-8), 
2.28-2.48 (m, 2H, H-3), 3.77 (d, 3H, JH9-P = 11.2 Hz, H-9), 
3.84 (d, 3H, JH9’-P = 11.2 Hz, H-9’), 4.08 (q, 2H, JH7-H8 = 
7.0 Hz, H-7), 4.46 – 4.60 (m, 1H, H-2), 4.88 (m, 1H, H-4), 
5.63 (d, 1H, JNH-H4 = 7.2 Hz, NH), 7.28 – 7.36 (m, 5H, Ph); 
13C NMR (CDCl3/TMS, 100 MHz) d 14.3 (C-8), 36.3 (C-
3), 51.6 (C-4), 54.6 (d, JC-P = 6.4 Hz, C-9), 54.8 (d, JC-P = 
5.6 Hz, C-9’), 60.8 (C-7), 72.4 (qd, JC-F = 33.0 Hz, JC-P = 
4.8 Hz, C-2), 126.6, 128.0, 128.9, 140.1 (6C, Ph), 123.4 
(qd, JC-F = 280.0 Hz, JC-P = 5.7 Hz, CF3), 155.7 (C-6); 19F 
NMR (CDCl3/fluorobenzene, 376.5 MHz) d -77.98; 31P 
NMR (CDCl3/H3PO4, 162.0 MHz) d -0.19; Anal. Calcd for 
C19H25F3NO6P (451.38): C, 45.12; H, 5.30; N, 3.51. Found: 
C, 45.14; H, 5.33; N, 3.39.
[3-(Diethoxy-phosphate)-4,4,4-trifluoro-1-phenyl-butyl]-
carbamic acid ethyl ester (2h) 
Yellow oil, 33%; MS EI (70ev): m/z (%) = 427 (M+, 4), 
382 (2), 272 (16), 244 (100), 200 (66), 155 (97), 127 (36), 
77 (22); 1H NMR (CDCl3/TMS, 200.13 MHz) d 1.20 (t, 3H, 
JH8-H7 = 7.0 Hz, H-8), 1.33 (t, 3H, JH10-H9 = 7.0 Hz, H-10), 
1.37 (t, 3H, JH10’-H9’ = 7.0 Hz, H-10’), 2.28 – 2.39 (m, 2H, 
H-3), 4.03 – 4.23 (m, 6H, H-7, H-9, H-9’), 4.48 – 4.62 (m, 
1H, H-2), 4.90 (m, 1H, H-4), 5.71 (d, 1H, JNH-H4 = 7.2 Hz, 
NH), 7.28 – 7.41 (m, 5H, Ph); 13C NMR (CDCl3/TMS, 100 
MHz) d 14.4 (C-8), 15.8 (d, JC-P = 7.2 Hz, C-10), 15.9 (d, 
JC-P = 6.4 Hz, C-10’), 36.5 (C-3), 51.7 (C-4), 60.8 (C-7), 
63.5 (d, JC-P = 5.5 Hz, C-9), 64.6 (d, JC-P = 6.4 Hz, C-9’), 
72.2 (qd, JC-F = 32.5 Hz, JC-P = 4.8 Hz, C-2), 126.3 (qd, 
JC-F = 230.9 Hz, CF3), 126.5, 127.9, 128.8, 140.4 (6C, Ph), 
155.7 (C-6); 19F NMR (CDCl3/fluorobenzene, 376.5 MHz) 
d -77.89; 31P NMR (CDCl3/H3PO4, 162.0 MHz) d -0.99; 
Anal. Calcd for C17H25F3NO6P (427.35): C, 47.78; H, 5.90; 
N, 3.28. Found: C, 47.40; H, 5.22; N, 3.87.
[3-(Bis-allyloxy-phosphate)-4,4,4-trifluoro-1-phenyl-
butyl]-carbamic acid ethyl ester (2i) 
Yellow oil, 30%; MS EI (70ev): m/z (%) = 451 (M+, 3), 
272 (29), 244 (100), 200 (76), 179 (63), 79 (32), 57 (12); 
1H NMR (CDCl3/TMS, 200.13 MHz) d 1.12 (t, 3H, JH8-H7 = 
7.2 Hz, H-8), 2.16 – 2.37 (m, 2H, H-3), 4.01 (q, 2H, JH7-H8 = 
7.2 Hz, H-7), 4.09 – 4.16 (m, 1H, H-4), 4.36 – 4.63 (m, 
5H, H-9, H-2), 5.13 – 5.44 (m, 4H, H-11), 5.81 – 6.00 (m, 
2H, H-10), 7.19 – 7.63 (5H, Ph); 13C NMR (CDCl3/TMS, 
100 MHz) d 14.4 (C-8), 36.4 (C-3), 44.5 (C-4), 60.9 (C-7), 
68.1 (d, JC-P = 3.4 Hz, C-9), 68.8 (d, JC-P = 5.6 Hz, C-9’), 
72.4 (qd, JC-F = 33.10 Hz, JC-P = 4.8 Hz, C-2), 118.2 (C-11), 
118.7 (C-11’), 123.4 (qd, JC-F = 280.0 Hz, JC-P = 6.2 Hz, 
CF3), 126.5, 128.0, 128.9, 140.3 (Ph), 131.8 (d, JC-P = 7.0 
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Hz, C-10), 132.2 (d, JC-P = 6.2 Hz, C-10’), 155.8 (C-6); 
Anal. Calcd for C19H25F3NO6P (451.38): C, 50.56; H, 5.58; 
N, 3.10. Found: C, 50.64; H, 5.43; N 3.38.
Acetylcholinesterase assays
All compounds 2a-i were tested at 1 µM for AChE (from 
Electrophorus electricus, Sigma Chemical Co.) inhibitory 
activity employing the spectrophotometric method of 
Ellman, as previously described.24,28
Molecular modeling studies
Docking protocol as implemented in FlexX (SYBYL 
7.3) and in GOLD 2.1 (Cambridge Crystallographic 
Data Centre, Cambridge, UK) was employed to search 
for the possible binding conformations of ligands in the 
AChE binding site. Crystallographic data for AChE in 
complex with o-ethylmethylphosphonic acid ester used in 
simulations in the FlexX were retrieved from Protein Data 
Bank (PDB code: 1VXR), to which removed the ligand 
from the active site, water molecules were removed and 
hydrogen atoms were added in standard geometry using the 
Biopolymer module as implemented in SYBYL 7.3. 
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